Astena Holdings Co., Ltd.

8095

JP3150000002

Pharmaceuticals

Delayed Japan Exchange Other stock markets 02:00:00 2024-04-26 am EDT			5-day change	1st Jan Change
488 ^JPY	+0.62%		+1.88%	+2.52%

2022	Tranche Update on Astena Holdings Co., Ltd.'s Equity Buyback Plan announced on July 13, 2022.	CI
2022	Astena Holdings Co., Ltd.'s Equity Buyback announced on July 13, 2022 has closed with 676,400 shares, representing 1.69% for ¥299.97 million.	CI

Tranche Update on Astena Holdings Co., Ltd.'s Equity Buyback Plan announced on July 13, 2022.

September 01, 2022 at 02:00 am EDT

From July 13, 2022 to August 31, 2022, the company has repurchased 474,800 shares, representing 1.19% for ¥209.35 million. With this, the company has completed the repurchase of 474,800 shares, representing 1.19% for ¥209.35 million under the buyback announced on July 13, 2022.

Latest news about Astena Holdings Co., Ltd.

Tranche Update on Astena Holdings Co., Ltd.'s Equity Buyback Plan announced on July 13, 2022.	22-09-21	CI
Astena Holdings Co., Ltd.'s Equity Buyback announced on July 13, 2022 has closed with 676,400 shares, representing 1.69% for ¥299.97 million.	22-09-15	CI
Tranche Update on Astena Holdings Co., Ltd.'s Equity Buyback Plan announced on July 13, 2022.	22-09-01	CI
Astena Holdings Co., Ltd. announces an Equity Buyback for 900,000 shares, representing 2.25% for ¥300 million.	22-07-13	CI
Astena Holdings Co., Ltd. authorizes a Buyback Plan.	22-07-12	CI
Insider Trends: MediciNova Insider Reports Option Conversion Extending 90-Day Buying Trend	21-07-23	MT
Tokyo Electric Power Incorporated : Olympic torch relay stirs mixed emotions ahead of its Fukushima start	21-03-24	RE
Tokyo Electric Power Incorporated : Olympic torch relay stirs mixed emotions ahead of its Fukushima start	21-03-23	RE
Daio Paper : Subsidiaries to Sell Shares in Parent Company	21-03-11	MT
Iwaki : Attributable Profit Drops Over 8% in Fiscal Nine Months 2020	21-03-08	MT
Insider Trends: Insider at MediciNova Converts Options Amid 90-Day Selling Trend	21-03-03	MT
Iwaki & Co., Ltd. cancelled the acquisition of Spera Pharma, Inc. from Bushu Pharmaceuticals Ltd.	21-01-23	CI
Iwaki & Co., Ltd. announced that it has received ¥9.6096 million in funding from SMBC Nikko Securities Inc., Investment Arm	20-12-15	CI
Iwaki & Co., Ltd. announced that it expects to receive ¥9.6096 million in funding from SMBC Nikko Securities Inc., Investment Arm	20-11-29	CI
Iwaki & Co., Ltd. agreed to acquire Maruman H&B Co.,Ltd. from MAJESTY GOLF Co., Ltd for ¥1 billion.	20-11-18	CI
Iwaki & Co., Ltd. signed a share transfer agreement to acquire Spera Pharma, Inc. from Bushu Pharmaceuticals Ltd. for ¥6 billion.	20-01-26	CI
Maeda Pharmaceutical Industry Co., Ltd. announced that it expects to receive funding from Iwaki & Co., Ltd.	20-01-26	CI
TechnoEcho Co., Ltd. acquired a 30% stake in Astena Holdings Co., Ltd..	19-12-25	CI
Iwaki Co., Ltd. agreed to acquire remaining 30% stake in TechnoEcho Co., Ltd. from Noriyuki Yamanaka and Makoto Nagase, Directors of Iwaki for approximately ¥160 million.	19-12-12	CI
Asco Co., Ltd. agreed to acquire Hokuyaku Co., Ltd. and A?M?I Co., Ltd. from Iwaki & Co., Ltd..	19-07-30	CI
Dalton Investments Submits Shareholder Proposal to Iwaki	18-11-19	CI
Iwaki & Co., Ltd.(TSE:8095) added to S&P Global BMI Index	17-09-18	CI
Iwaki Co., Ltd. completed the acquisition of 70% stake in TechnoEcho Co., Ltd.	16-12-25	CI
Iwaki Co., Ltd. agreed to acquire 70% stake in TechnoEcho Co., Ltd..	16-12-14	CI
Tranche Update on Iwaki & Co., Ltd.'s Equity Buyback Plan announced on April 12, 2016.	16-04-26	CI

Chart Astena Holdings Co., Ltd.

Duration

Period

More charts

Company Profile

Astena Holdings Co Ltd, formerly Iwaki & Co Ltd is a Japan-based company primarily engaged in the fine chemicals business, medical business, health & beauty care (HBC) and food business, and industrial chemicals business. The Company operates through four business segments. The Fine Chemicals segment is engaged in manufacture and sale of pharmaceutical raw materials and pharmaceuticals. The Medical segment is engaged in the manufacturing and sales of pharmaceutical products. The HBC and Food segment is engaged in the manufacture and sale of cosmetic raw materials, functional food raw materials, general use medicines and related products, as well as cosmetics. The Industrial Chemicals segment manufactures and sells chemicals for electronic industries, surface treatment chemicals, chemical products, surface treatment chemical raw materials, as well as to printed circuit board and other manufacturing plants. The other businesses include consulting services and others.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Ex-dividend day for dividende intermédiaire

More about the company

	1st Jan change	Capi.
ASTENA HOLDINGS CO., LTD.	+2.52%	123M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Astena Holdings Co., Ltd.

Equities

8095

JP3150000002

Pharmaceuticals

Tranche Update on Astena Holdings Co., Ltd.'s Equity Buyback Plan announced on July 13, 2022.

Latest news about Astena Holdings Co., Ltd.

Chart Astena Holdings Co., Ltd.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals